

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 17/08	A1	(11) International Publication Number: WO 98/04574 (43) International Publication Date: 5 February 1998 (05.02.98)
(21) International Application Number: PCT/US97/13166 (22) International Filing Date: 28 July 1997 (28.07.97) (30) Priority Data: 08/681,695 29 July 1996 (29.07.96) US 08/900,271 25 July 1997 (25.07.97) US (71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US). (72) Inventors: LIU, Jih-Hua; 31645 Rein Court, Green Oaks, IL 60048 (US). RILEY, David, A.; 5904 80th Place, Kenosha, WI 53142 (US). (74) Agents: ANAND, Mona et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).		(81) Designated States: AU, BR, CA, CN, CZ, IL, JP, KR, MX, NZ, SG, TR, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: PREPARATION OF CRYSTAL FORM II OF CLARITHROMYCIN (57) Abstract The present invention provides a process for the preparation of 6-O-methylerythromycin A Form II comprising converting erythromycin A to 6-O-methylerythromycin A and treating the 6-O-methylerythromycin A with a number of common organic solvents or mixtures of common organic solvents.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PREPARATION OF CRYSTAL FORM II OF CLARITHROMYCIN

This application is a continuation-in-part of copending U.S. application Serial Number 08/681,695, filed July 29, 1996.

5


Technical Field

This invention relates to a compound having therapeutic utility and to a method for its preparation. More particularly, the present invention concerns a process for the direct isolation of 6-*O*-methylerythromycin A crystal Form II.

10

Background of the Invention

6-*O*-methylerythromycin A (Clarithromycin, BIAXIN) is a semisynthetic macrolide antibiotic of formula



6-*O*-methyl erythromycin A

15

which exhibits excellent antibacterial activity against gram-positive bacteria, some gram-negative bacteria, anaerobic bacteria, *Mycoplasma*, and *Chlamidia*. It is stable under acidic conditions and is efficacious when administered orally. Clarithromycin is a useful therapy for infections of the upper respiratory tract in children and adults.

20

Brief Description of the Drawing

FIGS. 1a, 1b and 1c show, respectively, the powder X-ray diffraction spectrum, the infrared spectrum, and the differential scanning calorimetric (DSC) thermogram of 6-*O*-methylerythromycin A Form I.

25

FIGS. 2a, 2b and 2c show, respectively, the powder X-ray diffraction spectrum, the infrared spectrum, and the differential scanning calorimetric (DSC) thermogram of 6-*O*-methylerythromycin A Form II.

Summary of the Invention

We have discovered that 6-*O*-methylerythromycin A can exist in at least two distinct crystalline forms, which for the sake of identification are designated "Form I" and "Form II". The crystal forms are identified by their infrared spectrum, differential scanning calorimetric thermogram and powder x-ray diffraction pattern. Investigations in our laboratory have revealed that 6-*O*-methylerythromycin A when recrystallized from ethanol, tetrahydrofuran, isopropyl acetate, and isopropanol, or mixtures of ethanol, tetrahydrofuran, isopropyl acetate, or isopropanol with other common organic solvents result in exclusive formation of Form I crystals, not identified hitherto before. 6-*O*-methyl erythromycin A Form I is disclosed in the co-pending U.S. Application Serial No. 08/681,723, filed even-date on July 29, 1996.

Drugs currently on the market are formulated from the thermodynamically more stable Form II. Therefore, preparation of the current commercial entity requires converting the Form I crystals to Form II. Typically this is done by heating the Form I crystals under vacuum at a temperature of greater than 80 °C. Therefore, a process for the preparation of 6-*O*-methylerythromycin A Form II which does not require the high temperature treatment would result in substantial processing cost savings.

Although recrystallization from ethanol, tetrahydrofuran, isopropanol or isopropyl acetate results in exclusive formation of Form I crystals, 6-*O*-methylerythromycin A Form II can be isolated directly by using a number of other common organic solvents, or mixtures of common organic solvents, thereby eliminating the additional conversion step.

Accordingly, the present invention provides a process for preparing 6-*O*-methylerythromycin A Form II comprising

- (a) converting erythromycin A to 6-*O*-methylerythromycin A;
- (b) treating the 6-*O*-methylerythromycin A prepared in step (a) with a solvent selected from the group consisting of (i) an alkanol of from 1 to 5 carbon atoms, provided said alkanol is not ethanol or isopropanol, (ii) a hydrocarbon of from 5 to 12 carbon atoms, (iii) a ketone of from 3 to 12 carbon atoms, (iv) a carboxylic ester of from 3 to 12 carbon atoms, provided said carboxylic ester is not isopropyl acetate, (v) an ether of from 4 to 10 carbon atoms, (vi) benzene, (vii) benzene substituted with one or more substituents selected from the group consisting of alkyl of from one to four carbon atoms, alkoxy of from one to four carbon atoms, nitro, and halogen, (viii) a polar aprotic solvent, (ix) a compound having the formula HNR^1R^2 wherein R^1 and R^2 are independently selected from hydrogen and alkyl of one to four carbon atoms, provided that R^1 and R^2 are not both hydrogen, (x) water and a second solvent selected from the group consisting of a water miscible organic solvent and a water miscible alkanol, (xi) methanol and a second solvent selected from the group consisting of a hydrocarbon of from 5 to 12 carbon atoms, an alkanol of from 2 to 5 carbon atoms, a ketone of from 3 to 12 carbon atoms, a carboxylic ester of from 3 to 12 carbon atoms, an ether of from 4 to 10 carbon atoms,

benzene, and benzene substituted with one or more substituents selected from the group consisting of alkyl of from one to four carbon atoms, alkoxy of from one to four carbon atoms, nitro, and halogen, and (xii) a hydrocarbon of from 5 to 12 carbon atoms and a second solvent selected from the group consisting of a ketone of from 3 to 12 carbon atoms, a carboxylic ester of from 3 to 12 carbon atoms, an ether of from 4 to 10 carbon atoms, benzene, benzene substituted with one or more substituents selected from the group consisting of alkyl of from one to four carbon atoms, alkoxy of from one to four carbon atoms, nitro, and halogen, and a polar aprotic; and

(c) isolating the 6-*O*-methylerythromycin A Form II crystals.

10

Detailed Description

6-*O*-methylerythromycin A is prepared by methylation of the 6-hydroxy group of erythromycin A. However, in addition to the 6 position, erythromycin A contains hydroxy groups at the 11, 12, 2' and 4" positions, and a nitrogen at 3' position, all of which are potentially reactive with alkylating agents. Therefore, it is necessary to protect the various reactive functionalities prior to alkylation of the 6-hydroxy group. Representative 6-*O*-methylerythromycin A preparations are described in U.S. Pat. Nos. 4,331,803, 4,670,549, 4,672,109 and 4,990,602 and European Patent Specification 260 938 B1 which are incorporated herein by reference. Following final removal of the protecting groups, the 6-*O*-methylerythromycin A may exist as a solid, a semisolid, or a syrup containing residual solvents from the deprotection reactions, inorganic salts, and other impurities. 6-*O*-methylerythromycin A Form II may be crystallized directly from the syrup or semisolid using the solvent systems described above. Alternatively, if the crude reaction product solidifies, the solid may be recrystallized from any of the solvent systems described above. Pure 6-*O*-methylerythromycin A Form II may also be obtained by recrystallizing Form I or mixtures of Form I and Form II from any of the solvent systems described above. The term "6-*O*-methylerythromycin A" as used herein is meant to include 6-*O*-methylerythromycin A Form I or II in any state of purity, or mixtures thereof.

The term "treating" refers to crystallizing or recrystallizing 6-*O*-methylerythromycin A as defined above from any of the solvent systems described above.

The term "hydrocarbon" as used herein refers to straight chain or branched alkanes having the formula C_nH_{2n+2} . Hydrocarbons suitable for use in isolating 6-*O*-methylerythromycin A Form II crystals include hexane, heptane, octane and the like.

The term "alkyl" refers to a monovalent group derived from a straight or branched chain saturated hydrocarbon by the removal of a single hydrogen atom. Alkyl groups are exemplified by methyl, ethyl, *n*- and *iso*-propyl, *n*-, *sec*-, *iso*- and *tert*-butyl, and the like.

35

The term "ketone" refers to a solvent of formula $RC(O)R'$ where R and R' are straight or branched alkyl. Ketones suitable for use in isolating 6-O-methylerythromycin A Form II crystals include acetone, methyl ethyl ketone, 2-, and 3-pentanone, and the like.

5 The term "carboxylic ester" means a solvent of formula RCO_2R' where R and R' are straight or branched alkyl. Carboxylic esters suitable for use in isolating 6-O-methylerythromycin A Form II crystals include methyl acetate, ethyl acetate, isobutyl acetate, and the like.

10 The term "ether" means a solvent of formula ROR' where R and R' are straight or branched alkyl. Ethers suitable for use in isolating 6-O-methylerythromycin A Form II crystals include ethyl ether, diisopropyl ether, methyl *tert*-butyl ether, and the like.


15 The term "polar aprotic" refers to solvents which do not contain hydroxy groups but have a relatively high dipole moment. Polar aprotic solvents suitable for use in isolating 6-O-methylerythromycin A Form II crystals include acetonitrile, *N,N*-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,1-dimethoxyethane (DME), hexamethylphosphoric triamide (HMPA), and the like.

20 The term "water miscible organic solvents" means organic solvents which are substantially miscible with water. Examples of water miscible organic solvents suitable for use in isolating 6-O-methylerythromycin A Form II crystals from water miscible organic solvent-water mixtures include acetone, acetonitrile, *N,N*-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), tetrahydrofuran, dioxane, ethylene glycol diethyl ether, ethylene glycol dimethyl ether (glyme), and diethylene glycol dimethyl ether (diglyme).

The term "alkanol" refers to a hydrocarbon as defined above substituted with one or more hydroxy groups. Representative alkanols include methanol, propanol, isopropanol, butanol, isobutanol, ethylene glycol, and the like.

25 The term "water miscible alkanols" means an alkanol as defined above which is substantially miscible with water. Examples of water miscible alkanols suitable for use in isolating 6-O-methylerythromycin A Form II crystals from water miscible alkanol-water mixtures include methanol, ethanol, propanol, isopropanol, butanol, isobutanol and *tert*-butanol.

30 6-O-methylerythromycin A is prepared from erythromycin A by a variety of synthetic routes. In one method, erythromycin A is converted to 2'-O-3'-*N*-bis(benzyloxycarbonyl)-*N*-



demethylerythromycin A (I).

The 6-hydroxy


group is then methylated by reaction with an alkylating agent such as bromomethane or iodomethane and a base. Removal of the benzoyl groups by catalytic hydrogenation and reductive methylation of the 3' N gives 6-*O*-methylerythromycin A. See U.S. Pat. No.

5 4,331,803.

An alternative synthetic route involves methylation of 6-*O*-methylerythromycin A-9-oxime. 6-*O*-methylerythromycin A-9-oxime is prepared by methods well known in the art such as reaction of erythromycin A with hydroxylamine hydrochloride in the presence of base, or by reaction with hydroxylamine in the presence of acid as described in US Pat. No.

10 5,274,085. Reaction of the oxime with RX wherein R is allyl or benzyl and X is halogen results in formation of 2'-*O*,3'-*N*-diallyl or dibenzylerythromycin A-9-*O*-allyl or benzyloxime halide. Methylation of this quaternary salt as described above, followed by elimination of the R groups and deoximation gives 6-*O*-methylerythromycin A. See U.S. Pat. No. 4,670,549.

Methylation of 6-*O*-methylerythromycin A oxime derivatives of formula II,




15

II

wherein R is alkyl, alkenyl, substituted or

unsubstituted benzyl, oxyalkyl, or substituted phenylthioalkyl, R² is benzoyl, and R³ is methyl or benzoyl, followed by deprotection, deoximation, and reductive methylation when R³ is benzoyl gives 6-*O*-methylerythromycin A. See U.S. Pat. Nos. 4,672,109.

A particularly useful preparation of 6-*O*-methylethromycin A involves methylation of



the oxime derivative III,

III

wherein R^1 is alkenyl,


substituted or unsubstituted benzyl, or alkoxyalkyl, R^2 is substituted silyl, and R^3 is R^2 or H.

Removal of the protecting groups and deoximation is then accomplished in a single step by

5 treatment with acid to give 6-*O*-methylethromycin A. See European Patent Specification 260 938 B1 and U.S. Pat. No. 4,990,602.

A preferred route of 6-*O*-methylethromycin A is outlined in Scheme 1. Erythromycin A, prepared by fermentation of *Streptomyces erythreus* is oximated to give oxime 4 wherein R^1 is alkoxyalkyl. The group R^1 may be introduced by reaction of erythromycin A with the
 10 substituted hydroxylamine R^1ONH_2 , or by reaction of erythromycin A with hydroxylamine hydrochloride in the presence of base, or hydroxylamine in the presence of acid, followed by reaction with R^1X . The two hydroxy groups are then protected simultaneously, in which R^2 or R^3 are the same, or sequentially in which R^2 and R^3 are different. Particularly useful
 15 protecting groups are substituted silyl groups such as trimethylsilyl, *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl and the like. The protecting groups are then removed and the compound is deoximated to produce 6-*O*-methylethromycin A. The order of deprotection/deoximation is not critical. When the protecting groups are substituted silyl, deprotection and deoximation can be accomplished in a single step by treatment with acid, for example using formic acid or sodium hydrogen sulfite. See US. Pat. No. 4,990,602.

Scheme 1



- 5 The 6-O-methylerythromycin A prepared as described above is suspended in the desired solvent and heated to about the reflux temperature of the solvent. Heating is then continued and the suspension is stirred for an amount of time sufficient to dissolve most of the solid, generally about 10 minutes to 2 hours. The suspension is then filtered hot. If necessary, the filtrate may be heated to at or about the reflux temperature of the solvent to form
- 10 a clear solution. The filtrate is then slowly cooled to ambient temperature with optional further cooling in an ice-water bath. For purposes of this specification, ambient temperature is from about 20 to about 25 °C.

6-*O*-methylerythromycin A crystal Form II is isolated by filtration and dried in a vacuum oven at a temperature of between ambient temperature and about 50 °C, and a pressure of between about 2 inches of mercury and atmospheric pressure to remove any remaining solvent.

When 6-*O*-methylerythromycin A is treated with a water miscible organic solvent and
5 water or a water miscible alkanol and water, a suspension of 6-*O*-methylerythromycin A in the organic solvent or alkanol is heated to reflux and hot filtered. If necessary, the filtrate is heated at about the reflux temperature of the solvent until a clear solution is obtained. The clear solution is then mixed with water and cooled to ambient temperature with optional further cooling in an ice bath. The upper limit on the amount of water occurs when the mixture
10 separates into two liquid phases. A preferred ratio is about 1:1 parts by volume of water. After cooling, 6-*O*-methylerythromycin A crystal Form II is isolated by filtration and dried as described above. A preferred water miscible organic solvent is tetrahydrofuran. Preferred water miscible alkanols include methanol, ethanol, propanol and isopropanol.

In another aspect of the present invention, 6-*O*-methylerythromycin A is treated with
15 mixtures of methanol and a second solvent. In this case, the second solvent may include solvents such as ethanol, isopropanol, tetrahydrofuran or isopropyl acetate which normally result in formation of Form I crystals. Because the drug may have comparable solubilities in methanol and the second solvent, the amount of methanol must be carefully controlled to ensure maximum recovery. Preferred amounts of methanol are from about 1:3 to about 1:1
20 parts by volume. An especially preferred ratio is about 1:1 parts by volume of methanol. In accordance with this aspect of the invention, a suspension of 6-*O*-methylerythromycin A in the second solvent is heated to reflux and hot filtered. If necessary, the filtrate is heated at about the reflux temperature of the second solvent until a clear solution is obtained. The hot solution is then mixed with methanol and cooled to ambient temperature with optional further cooling in
25 an ice bath. Alternatively, when 6-*O*-methylerythromycin A has comparable solubility in both the second solvent and methanol, the second solvent and methanol are premixed in a ratio of about 1:1 parts by volume and the drug is suspended in a the solvent mixture, followed by heating, filtration, and cooling as described above. After cooling, 6-*O*-methylerythromycin A crystal Form II is isolated by
30 filtration and dried as described above.

In accordance with the aspects of this invention wherein 6-*O*-methylerythromycin A is treated with hydrocarbon-second solvent mixtures, 6-*O*-methylerythromycin A is suspended in the desired second solvent and heated to about the reflux temperature of the second solvent. The suspension is then heated and stirred for an amount of time sufficient to dissolve most of
35 the solid, generally about 10 minutes to 2 hours. The suspension is then filtered hot. The filtrate may be heated to reflux to form a clear solution if necessary. A hydrocarbon solvent is then added to the hot filtrate and the mixture is cooled slowly to ambient temperature with

optional further cooling in an ice bath. After cooling, 6-*O*-methylethromycin A crystal Form II is isolated by filtration and dried as described above. The amount of hydrocarbon solvent added is dependent on the solubility of the drug in the second solvent and the hydrocarbon solvent, and can be readily determined by one of ordinary skill in the art. Typical ratios fall in the range of about 1:10 to about 1:1 parts by volume of hydrocarbon solvent.

In a preferred embodiment, 6-*O*-methylethromycin A crystal Form II is isolated by treating 6-*O*-methylethromycin A with a solvent selected from the group consisting of acetone, heptane, toluene, methyl *tert*-butyl ether, *N,N*-dimethylformamide, ethyl acetate, xylene, ethyl ether, amyl acetate, diisopropyl ether, and isopropyl butyrate.

In a more preferred embodiment, 6-*O*-methylethromycin A crystal Form II is isolated by treating 6-*O*-methylethromycin A with water and a solvent selected from the group consisting of a water miscible organic solvent and a water miscible alkanol. An especially preferred water miscible organic solvent is tetrahydrofuran. Especially preferred water miscible alkanols are methanol, ethanol, propanol, and isopropanol.

When water is replaced with methanol in solvent mixtures, drying times are shortened or drying can be accomplished at a lower temperature. Therefore, in a still more preferred embodiment, 6-*O*-methylethromycin A crystal Form II is isolated by treating 6-*O*-methylethromycin A with a solvent comprising methanol and a second solvent selected from the group consisting of a hydrocarbon of from 5 to 12 carbon atoms, an alkanol of from 2 to 5 carbon atoms, a ketone of from 3 to 12 carbon atoms, a carboxylic ester of from 3 to 12 carbon atoms, an ether of from 4 to 10 carbon atoms, benzene, and benzene substituted with one or more substituents selected from the group consisting of alkyl of from one to four carbon atoms, alkoxy of from one to four carbon atoms, nitro, and halogen. Preferred solvents according to this embodiment are methanol and alkanols of from 2 to 5 carbon atoms, and methanol and carboxylic esters of from 3 to 12 carbon atoms. Especially preferred solvents are methanol-ethanol and methanol-isopropyl acetate.

In the most preferred embodiment of the present invention, 6-*O*-methylethromycin A crystal Form II is isolated by treating 6-*O*-methylethromycin A with a solvent having the formula HNR^1R^2 wherein R^1 and R^2 are independently selected from hydrogen and alkyl of one to four carbon atoms, provided that R^1 and R^2 are not both hydrogen. Alkyl and dialkylamines are preferred because 6-*O*-methylethromycin A is substantially soluble in these solvents and the solvents are readily evaporated, resulting in lower solvent and energy costs. The most preferred solvent is isopropylamine.

The foregoing may be better understood by reference to the following examples which are provided for illustration and not intended to limit the scope of the inventive concept.

Reference Example

6-*O*-methylethromycin A was prepared from erythromycin A by oximation of the C-9 carbonyl, protection of the C-2' and C-4'' hydroxy groups, methylation of the C-6 hydroxy group, deoximation and removal of the protecting groups, and recrystallization from ethanol according to the method of U.S. Pat. No. 4,990,602 to give 6-*O*-methylethromycin A Form I. The Form I crystals (0.40 g) were placed in a vial and heated in the vacuum oven (4-9 in Hg, 100-110 °C) for 18 hours to give 6-*O*-methylethromycin A Form II crystals.

6-*O*-methylethromycin A Form II is characterized by its infrared spectrum, the differential scanning calorimetric (DSC) thermogram and the powder x-ray diffraction pattern.

The differential scanning calorimetric thermogram is obtained by methods known in the art and is illustrated in Figure 2c. It can be seen from Figure 2c that 6-*O*-methylethromycin A Form II melts at 223.4 °C. In Figure 2c, an endothermic peak at 283.3 °C, which may be due to decomposition, can also be seen. After the DSC scan, the color of the sample was black.

The powder x-ray diffraction pattern for 6-*O*-methylethromycin A Form II is illustrated in Figure 2a. The powder x-ray diffraction pattern is obtained by methods known in the art using Nicolet X-ray Diffractometer. The peaks (with an intensity greater than 15% of the largest peak) generated from the powder x-ray diffraction pattern are compared with the corresponding peaks obtained from the calculated powder diffraction pattern. The calculated powder diffraction pattern is derived from the single x-ray structure, which is obtained by the methods known in the art using Rigaku AFC5R Diffractometer. The calculated powder pattern is used to confirm that the peaks in the experimentally observed x-ray pattern are due to clarithromycin Form II.

Table I below sets forth the 2-theta positions of the selected peaks (with an intensity greater than 15% of the largest peak). The standard positions in the Table I represent the peak positions from the experimental powder pattern rounded to 2 decimal places. One peak in the experimental powder pattern (15.280 2-theta) does not have a corresponding peak in the calculated powder pattern and, therefore, its position is not included in the listing of standard positions.

Table I**Powder Diffraction Peak Positions (degrees 2 Θ)**

x-ray ¹	Experimental	Difference	Standard Positions +/- 0.20
8.596	8.393	0.203	8.39
9.528	9.331	0.197	9.33
10.905	10.716	0.189	10.72
11.515	11.334	0.181	11.33
11.926	11.739	0.187	11.74

Table I
Powder Diffraction Peak Positions (degrees 2 θ) continued

x-ray ¹	Experimental	Difference	Standard Positions +/- 0.20
12.425	12.237	0.188	12.24
13.813	13.624	0.189	13.62
14.161	13.968	0.193	13.97
15.231	15.030	0.201	15.03
	15.280		
16.566	16.372	0.194	16.37
16.978	16.797	0.181	16.80
17.353	17.162	0.191	17.16
17.605	17.383	0.222	17.38
18.160	17.969	0.191	17.97
18.418	18.201	0.217	18.20
19.123	18.906	0.217	18.91
19.965	19.749	0.216	19.75
20.532	20.337	0.195	20.34
22.277	22.075	0.202	20.08
24.974	24.788	0.186	24.79

x-ray¹: calculated powder x-ray diffraction pattern

- 5 The standard 2-theta angle position from the Table I above are 8.39, 9.33, 10.72, 11.33, 11.74, 12.24, 13.62, 13.97, 15.03, 16.37, 16.80, 17.16, 17.38, 17.97, 18.20, 18.91, 19.75, 20.34, 20.08, and 24.79.

- 10 In comparison, the 2-theta angle positions in the powder x-ray diffraction pattern of 6-*O*-methylethromycin A Form I illustrated in Figure 1a are 8.52°±0.2, 9.48°±0.2, 10.84°±0.2, 11.48°±0.2, 11.88°±0.2, 12.36°±0.2, 13.72°±0.2, 14.12°±0.2, 15.16°±0.2, 16.48°±0.2, 16.92°±0.2, 17.32°±0.2, 18.08°±0.2, 18.40°±0.2, 19.04°±0.2, 19.88°±0.2, and 20.48°±0.2.

Example 1

15 Recrystallization from Acetone

A suspension of 6-*O*-methylethromycin A (30 g) in acetone (200 mL) was heated at reflux for 15 minutes. The hot solution was filtered and 5.53 g of solid was removed. The filter flask was rinsed with acetone (5 mL). The combined filtrate and rinse was warmed to

reflux and acetone (45 mL) was added to dissolve all remaining solid. The solution was cooled to ambient temperature and then in an ice-water bath. The resulting solid was filtered and dried overnight in a vacuum oven (4-9 in Hg, 40-45 °C) to give 6-*O*-methylerythromycin A Form II (17.8 g).

5

Example 2

Recrystallization from Heptane

A suspension of 6-*O*-methylerythromycin A (10 g) in heptane (1000 mL) was heated at reflux (98 °C) for 1.5 hours. The hot solution was filtered and 1.91 g of solid was removed.

10 The filtrate was warmed to reflux and heated for 35 minutes. The clear solution was cooled to ambient temperature and then in an ice-water bath. The resulting solid was filtered and dried overnight in a vacuum oven (4-9 in Hg, 40-45 °C) to give 6-*O*-methylerythromycin A Form II (5.7 g).

15

Example 3

Recrystallization from Toluene

A suspension of 6-*O*-methylerythromycin A (30 g) in toluene (100 mL) was heated at reflux (110-112 °C) for 1.5 hours. The hot solution was filtered and the filter flask was rinsed with toluene (10 mL). The combined filtrate and rinse was warmed to reflux (110 °C) and

20 heated for 35 minutes. The solution was cooled to ambient temperature and then in an ice-water bath. The resulting solid was filtered and dried overnight in a vacuum oven (4-9 in Hg, 40-45 °C) to give 6-*O*-methylerythromycin A Form II (5.7 g).

25

Example 4

Recrystallization from Methyl *tert*-Butyl Ether

A suspension of 6-*O*-methylerythromycin A (10 g) in methyl *tert*-butyl ether (200 mL) was heated at reflux (55 °C) for 15 minutes. The hot solution was filtered and 2.6 g of solid was removed. The filtrate was warmed to reflux and methyl *tert*-butyl ether (70 mL) was added to dissolve the remaining solid. The solution was cooled to ambient temperature and

30 then in an ice-water bath. The resulting solid was filtered and dried overnight in a vacuum oven (4-9 in Hg, 40-45 °C) to give 6-*O*-methylerythromycin A Form II (4.6 g).

Example 5

Recrystallization from *N,N*-Dimethylformamide

35 A suspension of 6-*O*-methylerythromycin A (20 g) in *N,N*-dimethylformamide (200 mL) was heated at reflux (153 °C) for 15 minutes. The hot solution was filtered and the filtrate was warmed to reflux. The clear solution was cooled slowly to ambient temperature and

stirred for four days. The resulting solid was filtered and dried overnight in a vacuum oven (4-9 in Hg, 40-45 °C) to give 6-*O*-methylerythromycin A Form II (7.4 g).

Example 6

5

Recrystallization from Ethyl Acetate

A suspension of 6-*O*-methylerythromycin A (15 g) in ethyl acetate (100 mL) was heated at reflux (77 °C) for 30 minutes. The hot solution was filtered and the filtrate was warmed to reflux. To the cloudy solution was added ethyl acetate (15 mL). The resulting clear solution was cooled to ambient temperature overnight. The resulting solid was filtered and
10 dried in a vacuum oven (4-9 in Hg, 40-45 °C) for 91 hours to give 6-*O*-methylerythromycin A Form II (8.7 g).

Example 7

Recrystallization from Xylene

15

A suspension of 6-*O*-methylerythromycin A (35 g) in xylene (105 mL) was heated to 140 °C at which point a clear solution was obtained. Additional 6-*O*-methylerythromycin A (5.0 g) was added and the hot solution was filtered to remove a trace amount of insoluble material. The filter flask was rinsed with xylene (5 mL) and the combined filtrate and rinse were heated at reflux for 15 minutes. The solution was cooled to ambient temperature and then
20 in an ice water bath. The resulting solid was filtered and dried overnight in a vacuum oven (4-9 in Hg, 40-45 °C) to give 6-*O*-methylerythromycin A Form II (29 g).

Example 8

Recrystallization from Isopropanol-Water

25

A suspension of 6-*O*-methylerythromycin A (20 g) and isopropanol (100 mL) was heated to reflux (82 °C). The hot solution was filtered and 1.16 g of solid was removed. The filtrate was diluted with isopropanol (20 mL) and was again warmed to reflux. The hot suspension was filtered and 3.5 g of 6-*O*-methylerythromycin A was collected. To the filtrate was added isopropanol (50 mL) and the mixture was heated at reflux until a clear solution was
30 obtained. To the clear solution was added water (100 mL) and the solution was cooled in an ice bath. The resulting solid was filtered and dried overnight in a vacuum oven (4-9 in Hg, 40-45 °C) to give 6-*O*-methylerythromycin A Form II (9.5 g).

Example 9

35

Recrystallization from Tetrahydrofuran-Water

A suspension of 6-*O*-methylerythromycin A (30 g) in THF (100 mL) was heated at reflux (66.5 °C) for 20 minutes. The hot solution was filtered to remove a trace amount of

insoluble material. The filtrate was warmed to (66.5 °C) and water (100 mL) was added at which point a solid formed. The suspension was cooled to ambient temperature and filtered. The solid was dried in a vacuum oven (4-9 in Hg, 40-45 °C) for four days to give 6-*O*-methylerythromycin A Form II (24 g).

5

Example 10

Recrystallization from Ethanol-Water

A suspension of 6-*O*-methylerythromycin A (20 g) in ethanol (200 mL) was heated to 78 °C. The hot solution was filtered and 12.6 g of solid was removed. The filtrate was
10 warmed to reflux and water (200 mL) was added. The mixture was cooled to ambient temperature and filtered. The solid was dried in a vacuum oven (4-9 in Hg, 40-45 °C) to give 6-*O*-methylerythromycin A Form II (8.8 g).

Example 11

Recrystallization from Ethyl Ether

15

A suspension of 6-*O*-methylerythromycin A (5.0 g) in ethyl ether (150 mL) was warmed to reflux. The insoluble solids were removed by filtration and the filtrate was cooled to ambient temperature. A precipitate slowly appeared and was isolated by filtration to give 6-*O*-methylerythromycin A Form II (0.8 g). The filtrate was stirred overnight at ambient
20 temperature to give an additional 0.65 g of 6-*O*-methylerythromycin A Form II.

Example 12

Recrystallization from Amyl Acetate

A suspension of 6-*O*-methylerythromycin A in amyl acetate (100 mL) was warmed 93
25 °C at which point the solution was almost clear. A trace amount of insoluble solids were removed by filtration of the hot solution and the filtrate was cooled to ambient temperature. A precipitate slowly appeared and was isolated by filtration to give 6-*O*-methylerythromycin A Form II (6.9 g) after drying overnight at ambient temperature (4-9 in Hg).

30

Example 13

Recrystallization from Isopropyl Acetate-Methanol

A suspension of 6-*O*-methylerythromycin A (12 g) in isopropyl acetate (100 mL) was warmed to reflux. The hot solution was filtered and the filtrate was transferred to another vessel. The filter flask was rinsed with isopropyl acetate (10 mL) and the combined filtrate and
35 rinse were warmed to reflux. Methanol (100 mL) was added and the clear solution was cooled slowly to ambient temperature during which time a precipitate formed. After three hours at

ambient temperature the precipitate was collected by filtration. The solid was dried in a vacuum oven (4-9 in Hg, 40-45 °C) to give 6-*O*-methylerythromycin A Form II (6.8 g).

Example 14

5

Recrystallization from Diisopropyl Ether

A suspension of 6-*O*-methylerythromycin A (3.0 g) and diisopropyl ether (150 mL) was warmed to reflux. The hot solution was filtered rapidly and the filtrate was cooled to ambient temperature over two hours. The resulting solid was collected by filtration and dried in the vacuum oven (7-9 in Hg, 45-50 °C) to give 6-*O*-methylerythromycin A Form II (0.27 g).

10

Example 15

Recrystallization from Isopropyl Butyrate

A suspension of 6-*O*-methylerythromycin A (5.0 g) in isopropyl butyrate (100 mL) was warmed to 90 °C. The resulting clear solution was cooled to ambient temperature over three hours and then was cooled for 30 minutes in an ice-water bath. The resulting solid was collected by filtration and dried in the vacuum oven (2-4 in Hg, 45-50 °C) to give 6-*O*-methylerythromycin A Form II (2.8 g).

15

Example 16

20

Recrystallization from Isopropylamine

A clear solution resulting from addition of 6-*O*-methylerythromycin A (8.0 g) to isopropylamine (50 mL) was stirred overnight at ambient temperature. When no precipitate formed, and additional 10.4 g of 6-*O*-methylerythromycin A was added. The clear solution was stirred overnight at ambient temperature during which time a precipitate formed. The solid was collected by filtration and dried in the vacuum oven (2-4 in Hg, 45-50 °C) to give 6-*O*-methylerythromycin A Form II (16.2 g).

25

Example 17

Recrystallization from Methanol-Ethanol

A mixture of 6-*O*-methylerythromycin A (15 g), ethanol (100 mL) and methanol (100 mL) was warmed to 69 °C and stirred for 30 minutes. The hot solution was filtered and the filtrate was transferred to another vessel. The clear solution was cooled to ambient temperature over two hours and then was stirred for 30 minutes in an ice-water bath. The resulting solid was collected by filtration and dried in the vacuum oven (2-4 in Hg, 45-50 °C) to give 6-*O*-methylerythromycin A Form II (7.1 g).

35

The foregoing examples are presented for purposes of illustration and are not intended to limit the scope of the invention. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention as defined in the appended claims.

WE CLAIM:


1. A method of preparing 6-*O*-methylerythromycin A crystal Form II comprising
- (a) converting erythromycin A to 6-*O*-methylerythromycin A;
 - (b) treating the 6-*O*-methylerythromycin A prepared in step d with a solvent selected from the group consisting of
 - 5 (i) an alkanol of from 1 to 5 carbon atoms, provided said alkanol is not ethanol or isopropanol.
 - (ii) a hydrocarbon of from 5 to 12 carbon atoms,
 - (iii) a ketone of from 3 to 12 carbon atoms,
 - 10 (iv) a carboxylic ester of from 3 to 12 carbon atoms, provided said carboxylic ester is not isopropyl acetate,
 - (v) an ether of from 4 to 10 carbon atoms,
 - (vi) benzene,
 - (vii) benzene substituted with one or more substituents selected from the group consisting of
 - 15 alkyl of from one to four carbon atoms,
 - alkoxy of from one to four carbon atoms,
 - nitro, and
 - halogen,
 - (viii) a polar aprotic solvent,
 - 20 (ix) a compound having the formula HNR^1R^2 wherein R^1 and R^2 are independently selected from hydrogen and alkyl of one to four carbon atoms, provided that R^1 and R^2 are not both hydrogen,
 - (x) water and a water miscible solvent selected from the group consisting of
 - 25 a water miscible organic solvent and
 - a water miscible alkanol,
 - (xi) methanol and a second solvent selected from the group consisting of
 - 30 a hydrocarbon of from 5 to 12 carbon atoms,
 - an alkanol of from 2 to 5 carbon atoms,
 - a ketone of from 3 to 12 carbon atoms,
 - a carboxylic ester of from 3 to 12 carbon atoms,
 - 35 an ether of from 4 to 10 carbon atoms,
 - benzene, and
 - benzene substituted with one or more substituents selected from the group consisting of
 - alkyl of from one to four carbon atoms,
 - alkoxy of from one to four carbon atoms,

- nitro, and
halogen, and
- (xii) a hydrocarbon of from 5 to 12 carbon atoms and a second solvent
40 selected from the group consisting of
a ketone of from 3 to 12 carbon atoms,
a carboxylic ester of from 3 to 12 carbon atoms,
an ether of from 4 to 10 carbon atoms,
benzene,
45 benzene substituted with one or more substituents selected from
the group consisting of
alkyl of from one to four carbon atoms,
alkoxy of from one to four carbon atoms,
nitro, and
50 halogen, and
a polar aprotic; and
- (f) isolating the 6-*O*-methylethromycin A Form II crystals.
2. The process of claim 4 wherein step (a) comprises
- (i) converting erythromycin A into an erythromycin A 9-oxime derivative;
(ii) protecting the 2' and 4'' hydroxy groups of the erythromycin A 9-oxime
derivative prepared in step a;
5 (iii) reacting the product of step b with a methylating agent;
(iv) deprotecting and deoximating the product of step c to form
6-*O*-methylethromycin A.
3. A method according to Claim 2 wherein the solvent comprises water and a water
miscible organic solvent or a water miscible alkanol.
4. A method according to Claim 3 wherein the solvent comprises water and a water
miscible organic solvent or water miscible alkanol in a ratio of about 1:1 parts by
volume.
5. A method according to Claim 4 wherein the solvent comprises water and a water
miscible organic solvent.
6. A method of preparing 6-*O*-methylethromycin A crystal Form II according to Claim 5
wherein water miscible organic solvent is tetrahydrofuran.

7. A method according to Claim 4 comprising wherein the solvent comprises water and a water miscible alkanol.
8. A method according to Claim 7 wherein water miscible alkanol is selected from the group consisting of methanol, ethanol, and isopropanol.
9. A method of according to Claim 2 wherein the solvent comprises methanol and a second solvent selected from the group consisting of
- 5 a hydrocarbon of from 5 to 12 carbon atoms,
an alkanol of from 2 to 5 carbon atoms,
a ketone of from 3 to 12 carbon atoms,
a carboxylic ester of from 3 to 12 carbon atoms,
an ether of from 4 to 10 carbon atoms,
benzene, or
benzene substituted with one or more substituents selected from the
- 10 group consisting of
alkyl of from one to four carbon atoms,
alkoxy of from one to four carbon atoms,
nitro, and
halogen.
- 15
10. A method according to Claim 9 wherein the solvent comprises methanol and
an alkanol of from 2 to 5 carbon atoms, or
a carboxylic ester of from 3 to 12 carbon atoms.
11. A method according to Claim 10 wherein the solvent comprises methanol and an
alkanol of from 2 to 5 carbon atoms, or a carboxylic ester of from 3 to 12 carbon atoms
in a ratio of about 1:1 parts by volume.
12. A method according to Claim 11 wherein the solvent comprises methanol and a second
solvent selected from ethanol and isopropyl acetate.
13. A method according to Claim 2 wherein the solvent comprises a compound of formula
 HNR^1R^2 wherein R^1 and R^2 are independently selected from hydrogen and alkyl of
one to four carbon atoms, provided that R^1 and R^2 are not both hydrogen.

14. A method according to Claim 13 wherein the solvent is isopropylamine.
15. A method according to Claim 2 wherein the solvent is selected from the group consisting of
- acetone,
 - heptane,
 - 5 toluene,
 - methyl *tert*-butyl ether,
 - N,N*-dimethylformamide,
 - ethyl acetate,
 - xylene,
 - 10 isopropanol-water,
 - tetrahydrofuran-water,
 - ethanol-water,
 - ethyl ether,
 - amyl acetate,
 - 15 isopropyl acetate-methanol
 - diisopropyl ether,
 - isopropyl butyrate,
 - isopropylamine, and
 - 20 methanol-ethanol.
16. 6-*O*-methylethromycin A Form II prepared according to the process of Claim 2.

1/6

**FIG.1a**

2/6




FIG.1b




FIG.1c

4/6




FIG.2a

5/6




FIG.2b




FIG.2c

INTERNATIONAL SEARCH REPORT

Inter' nal Application No
PCT/US 97/13166

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07H17/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	K.H.KIM ET AL.: "Conformational Study of Erythromycin Analogues." QSAR : QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS IN DRUG DESIGN, vol. 291, 1989, pages 325-328, XP002043674	1
X	see the whole document	16
A	--- H.IWASAKI ET AL.: "Structure of 6-O-Methylerythromycin A (Clarithromycin)." ACTA CRYSTALLOGRAPHICA , vol. c49, no. 5, 15 May 1993, pages 1227-1230, XP002043675	1
X	see the whole document ---	16
- / - -		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

15 October 1997

Date of mailing of the international search report

27. 10 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scott, J

INTERNATIONAL SEARCH REPORT

Internat. Application No
PCT/US 97/13166

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 990 602 A (MORIMOTO SHIGEO ET AL) 5 February 1991 cited in the application see the whole document ---	1
P,A	WO 97 19096 A (ABBOTT LAB) 29 May 1997 see the whole document -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/13166

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4990602 A	05-02-91	DE 3785315 A EP 0272110 A JP 2526951 B JP 63264495 A KR 9600434 B	13-05-93 22-06-88 21-08-96 01-11-88 06-01-96
-----	-----	-----	-----
WO 9719096 A	29-05-97	NONE	
-----	-----	-----	-----